Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting
- PMID: 21417835
- DOI: 10.1517/14740338.2011.563235
Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting
Abstract
Introduction: Aprepitant is the only neurokinin (NK(1)) receptor antagonist (RA) approved for prevention of chemotherapy-induced nausea and vomiting (CINV). Aprepitant is co-administered with a 5-HT(3) RA and a corticosteroid. Although aprepitant is safe, in most clinical settings potential drug-drug interactions need to be considered before prescription.
Areas covered: This article thoroughly reviews aprepitant and, in particular, clinically relevant safety aspects of the drug. The literature review was performed using Medline with the following search terms: adverse events, aprepitant, chemotherapy, CYP3A4, MK-0869, neurokinin(1) receptor antagonist, safety and tolerability.
Expert opinion: The recommended antiemetic regimen of aprepitant, a 5-HT(3) RA and a corticosteroid is safe. The combination of aprepitant, a 5-HT(3) RA and dexamethasone is now the gold standard of antiemetic treatment in prevention of CINV induced by HEC, or by the combination of an anthracycline and cyclophosphamide. The intravenous formulation of aprepitant used as a single dose is expected to be of benefit to cancer patients.
Similar articles
-
Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):481-8. doi: 10.1586/erp.11.47. Epub 2011 Jun 28. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 21711119
-
Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting.Ann Pharmacother. 2005 Jan;39(1):77-85. doi: 10.1345/aph.1E242. Epub 2004 Nov 23. Ann Pharmacother. 2005. PMID: 15562136 Review.
-
Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1607-14. doi: 10.1517/17425250903451675. Expert Opin Drug Metab Toxicol. 2009. PMID: 19929449 Review.
-
Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.Expert Rev Anticancer Ther. 2008 Nov;8(11):1733-42. doi: 10.1586/14737140.8.11.1733. Expert Rev Anticancer Ther. 2008. PMID: 18983233 Review.
-
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.Cancer. 2003 Jun 15;97(12):3090-8. doi: 10.1002/cncr.11433. Cancer. 2003. PMID: 12784346 Clinical Trial.
Cited by
-
Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia.Front Oncol. 2023 Jan 17;12:1075559. doi: 10.3389/fonc.2022.1075559. eCollection 2022. Front Oncol. 2023. PMID: 36733367 Free PMC article. Review.
-
Cardiovascular events in cancer patients treated with highly or moderately emetogenic chemotherapy: results from a population-based study.J Cancer Epidemiol. 2012;2012:529357. doi: 10.1155/2012/529357. Epub 2012 Apr 12. J Cancer Epidemiol. 2012. PMID: 22570656 Free PMC article.
-
The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.J Biosci. 2015 Jun;40(2):441-63. doi: 10.1007/s12038-015-9530-8. J Biosci. 2015. PMID: 25963269 Review.
-
Gastroparesis: concepts, controversies, and challenges.Scientifica (Cairo). 2012;2012:424802. doi: 10.6064/2012/424802. Epub 2012 Aug 8. Scientifica (Cairo). 2012. PMID: 24278691 Free PMC article. Review.
-
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.Oncotarget. 2013 Apr;4(4):502-30. doi: 10.18632/oncotarget.969. Oncotarget. 2013. PMID: 23594434 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
